Table 1: Study characteristics and outcomes.
Author (year) |
Country&
Participants |
Design |
Journal |
J.
Impact Factor. |
Conclusion |
|
Swithinbank L. (2005) |
UK N =
69 |
Prospective
Observational cross
over study |
Journal
of Urology |
3.746 |
Caffeine
restriction does not improve symptoms Increased symptoms with higher fluid
intake P = 0.006 |
|
Tomlinson
B.U (2009) |
USA N =
218 |
Quasi-expermental design |
Int Urogynecology
Journal |
2.16 |
Caffeine
restriction to 100 mg showed a positive relation with reduction of urinary
episodes (P = 0.074) |
|
Bryant
Ch. (2002) |
Australia N =
96 |
RCT |
British
Journal of
Nursing |
0.47 |
Significant
reduction in caffeine consumption and less occasions of urgency in
experimental group (P = 0.002) |
|
Townsed M. (2012) |
USA N =
21.564 |
Prospective
cohort |
Obstetrics
and Gynecolgy J. |
4.73 |
No
association with caffeine intake reduction and symptoms were Observed OR 0.87
(0.70-1.08) |
|
Jura
Y.H. (2011) |
USA N = 65.176 |
Prospective
cohort |
Journal
of Urology |
3.746 |
Incidence
of urgency incontinence was associated with high intake of caffeine > 300
mg/day RR: 1,19 (1.06 - 01.34) |
|
Arya
L (2000) |
USA N =
259 |
Case
Control |
Obstetrics
and Gynecology J. |
4.79 |
Very
high intake of caffeine (> 400 mg/day) was significantly associated with
higher odds of detrusor instability OR 2.4 (1.1, 6.5) p = 0.006 |
|
Bradley
(2005) |
USA N =
297 |
Longitudinal
observational study |
Journal
of Women´s Health |
0.57 |
Association
with difficulty in emptying bladder OR 5.3 (1.2-23.0), P = 0.06 |
|
Hirayama
F. (2012) |
Japan N =
298 |
Cross-sectional |
J Prev Med Public Health. |
0.235 |
No
association observed OR 1.12 (0.57-2.22) P = 0.44 |
|
Hannestad (2003) |
Norway N =
27936 |
Cross-sectional |
Int.
J. of Obstetrics and Gynecology |
2.045 |
No
association observed with coffee. OR 1.0 (0.9-1.1) Significant association
with tea. OR 1.3 (1.2 -1.5) |
|
Gleason
J. (2012) |
USA N =
4309 |
Cross-sectional |
Int.
Urogynec J. |
2.16 |
Prevalence
of any UI was associated with caffeine intake ≥ 204 mg/day (POR 1.42,
95% CI 1.07-2.07) |